Evidence map›Paper›PMID 36338670›Full record

ArticleMolecular vision2022

Sulforaphane recovers cone function in an Nrf2-dependent manner in middle-aged mice undergoing RPE oxidative stress.

Xiaoping Qi, Dorothy A Walton, Kendra S Plafker, Michael E Boulton, Scott M Plafker

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Sulforaphane and ophthalmic diseases.Food science & nutrition · 2024
    Review
  6. Review
  7. Article
  8. Drug-Repurposing Strategy for Dimethyl Fumarate.Pharmaceuticals (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaoping QiDepartment of Ophthalmology and Visual Sciences, University of Alabama at Birmingham (UAB), Birmingham, AL.
Dorothy A WaltonAging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.
Kendra S PlafkerAging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.
Michael E BoultonDepartment of Ophthalmology and Visual Sciences, University of Alabama at Birmingham (UAB), Birmingham, AL.
Scott M PlafkerAging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.
Oklahoma Medical Research Foundation · USUniversity of Alabama at Birmingham Hospital · US

Funding

Mitochondrial Dynamics in RPE Homeostasis and DiseaseR01EY024944 · NEI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI PLAFKER, SCOTT M · 2018 to 2021
$2.2M
NEI NIH HHS R01 EY024944
6 · The paper itself

Abstract

Purpose: Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables that has therapeutic efficacy in numerous animal models of human disease, including mouse models of retinal degeneration. However, despite dozens of clinical trials, the compound remains to be tested as a clinical treatment for ocular disease. Numerous cellular activities of SFN have been identified, including the activation of Nrf2, a transcription factor that induces a battery of target gene products to neutralize oxidative and xenobiotic stresses. As Nrf2 expression and function reportedly decrease with aging, we tested whether the loss of the transcription factor limits the therapeutic efficacy of SFN against retinal degeneration. Methods: Six- to 8-month-old wild-type and Nrf2 knockout mice were treated with SFN beginning 1 month after ribozyme-mediated knockdown of superoxide dismutase 2 (SOD2) mRNA in the RPE. The impacts of MnSOD (the protein product of SOD2) knockdown and the efficacy of SFN were evaluated using a combination of electroretinography (ERG), spectral domain optical coherence tomography (SD-OCT), and postmortem histology. Results: SFN restored the ERG photopic b-wave suppressed by MnSOD loss in wild-type mice, but not in the Nrf2 knockout mice. In contrast, ERG scotopic a- and b-wave loss was not restored for either genotype. SFN significantly improved retinal thickness in the Nrf2 knockout mice with MnSOD knockdown, but this was not observed in the wild-type mice. In both genotypes, SFN treatment reduced morphological markers of RPE atrophy and degeneration, although these improvements did not correlate proportionally with functional recovery. Conclusions: These findings highlight the capacity of SFN to preserve cone function, as well as the potential challenges of using the compound as a standalone treatment for age-related retinal degeneration under conditions associated with reduced Nrf2 function.

Indexed as

NF-E2-Related Factor 2Retinal DegenerationAnimalsHumansInfantIsothiocyanatesMiceMice, KnockoutOxidative StressRetinal Pigment EpitheliumSulfoxidesIsothiocyanatesNF-E2-Related Factor 2sulforaphaneSulfoxides

Identifiers

PMID36338670
PMCPMC9603948
OpenAlexW4308679791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.